A detailed history of Black Rock Inc. transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 9,197,040 shares of ATOS stock, worth $9.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,197,040
Previous 2,751,263 234.28%
Holding current value
$9.47 Million
Previous $4.95 Million 121.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$1.03 - $2.1 $6.64 Million - $13.5 Million
6,445,777 Added 234.28%
9,197,040 $10.9 Million
Q1 2024

May 10, 2024

SELL
$0.8 - $1.89 $36,139 - $85,378
-45,174 Reduced 1.62%
2,751,263 $4.95 Million
Q4 2023

Feb 13, 2024

SELL
$0.63 - $0.98 $56,750 - $88,278
-90,080 Reduced 3.12%
2,796,437 $2.46 Million
Q3 2023

Nov 13, 2023

SELL
$0.74 - $1.35 $8,842 - $16,131
-11,949 Reduced 0.41%
2,886,517 $2.14 Million
Q2 2023

Aug 11, 2023

SELL
$0.6 - $1.28 $183,639 - $391,763
-306,065 Reduced 9.55%
2,898,466 $3.65 Million
Q1 2023

May 12, 2023

SELL
$0.59 - $0.91 $151,785 - $234,109
-257,263 Reduced 7.43%
3,204,531 $2.31 Million
Q4 2022

Feb 13, 2023

SELL
$0.5 - $1.01 $36,540 - $73,811
-73,081 Reduced 2.07%
3,461,794 $1.83 Million
Q3 2022

Nov 14, 2022

SELL
$0.82 - $1.14 $44,122 - $61,341
-53,808 Reduced 1.5%
3,534,875 $2.95 Million
Q2 2022

Aug 12, 2022

SELL
$0.85 - $1.28 $4.97 Million - $7.49 Million
-5,848,351 Reduced 61.97%
3,588,683 $3.91 Million
Q1 2022

May 12, 2022

SELL
$1.11 - $1.74 $113,840 - $178,452
-102,559 Reduced 1.08%
9,437,034 $11.8 Million
Q4 2021

Feb 10, 2022

SELL
$1.6 - $3.27 $17,657 - $36,087
-11,036 Reduced 0.12%
9,539,593 $15.3 Million
Q3 2021

Nov 09, 2021

BUY
$2.89 - $6.4 $1.72 Million - $3.82 Million
596,336 Added 6.66%
9,550,629 $31.1 Million
Q2 2021

Aug 11, 2021

BUY
$1.52 - $8.62 $13.6 Million - $77.2 Million
8,954,293 New
8,954,293 $56.6 Million

Others Institutions Holding ATOS

About ATOSSA THERAPEUTICS, INC.


  • Ticker ATOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,624,000
  • Market Cap $130M
  • Description
  • Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...
More about ATOS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.